Exicure Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Exicure yıllık ortalama 14.9% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19% annual. Gelirler yılda ortalama 12.5% oranında büyüyor .

Anahtar bilgiler

14.9%

Kazanç büyüme oranı

29.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	12.5%
Özkaynak getirisi	-506.6%
Net Marj	-1,634.4%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Aug 29

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Sep 26

Exicure Q2 GAAP loss per share narrows, revenue up

Aug 15

Exicure regains compliance with Nasdaq's minimum bid price requirement

Jul 20

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Jun 29

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Aug 25

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Mar 10

Gelir ve Gider Dağılımı

Exicure nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:XCUR Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	1	-8	6
31 Mar 24	1	-13	11
31 Dec 23	0	-17	13
30 Sep 23	22	3	13
30 Jun 23	24	3	13
31 Mar 23	26	1	11
31 Dec 22	29	-3	11
30 Sep 22	9	-35	13
30 Jun 22	3	-53	13
31 Mar 22	1	-60	13
31 Dec 21	0	-64	13
30 Sep 21	-2	-63	12
30 Jun 21	4	-48	11
31 Mar 21	8	-38	10
31 Dec 20	17	-25	10
30 Sep 20	17	-22	9
30 Jun 20	15	-19	9
31 Mar 20	10	-20	9
31 Dec 19	1	-26	9
30 Sep 19	1	-21	8
30 Jun 19	1	-21	8
31 Mar 19	0	-22	8
31 Dec 18	0	-22	8
30 Sep 18	2	-21	8
30 Jun 18	5	-18	8
31 Mar 18	7	-14	8
31 Dec 17	10	-11	7
30 Sep 17	8	-13	6
30 Jun 17	6	-15	5
31 Mar 17	3	-16	4
31 Dec 16	1	-17	4
31 Dec 15	2	-6	5

Kaliteli Kazançlar: XCUR şu anda kârlı değil.

Büyüyen Kar Marjı: XCUR şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: XCUR kârlı değildir, ancak son 5 yılda zararlarını yılda 14.9% oranında azaltmıştır.

Büyüme Hızlandırma: XCUR 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: XCUR kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -2.3% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: XCUR hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -506.63% ) sahiptir.

Exicure Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Recent updates

New minor risk - Shareholder dilution

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Exicure, Inc., Annual General Meeting, Jun 28, 2024

Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure, Inc. Announces Executive Changes

Exicure, Inc. Contemplates Bankruptcy

Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc.

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Exicure Receives Noncompliance Notice from Nasdaq

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure regains compliance with Nasdaq's minimum bid price requirement

Exicure Announces Receipt of Nasdaq Notice of Non-Compliance

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, May 27, 2022

Exicure, Inc. Announces Executive, Board and Committee Changes

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors

Exicure Receives A Letter from the Staff Nasdaq Stock Market

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc

Price target decreased to US$6.75

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$12.9m

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Consensus revenue estimates increase to US$22.1m

Price target decreased to US$9.00

Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index

Consensus revenue estimates fall to US$5.77m

Price target decreased to US$9.60

Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Co-Founder & Director Chad Mirkin has left the company

Consensus revenue estimates increase to US$8.91m

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Exicure, Inc. Announces Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients with Glioblastoma

Exicure, Inc. Announces David R. Walt Did Not Stand for Re Election

Exicure Announces Appointments of Board of Directors

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

New 90-day high: US$2.80

Exicure Appoints James Sulat to Board of Directors